Pirfenidone Treatment for Patients with Atypical Liver Function
First Claim
1. A method of administering pirfenidone to treat a patient who would benefit from pirfenidone administration, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, comprising (a) administering to said patient pirfenidone at doses of at least 1600 mg/day or 1602 mg/day.
3 Assignments
0 Petitions
Accused Products
Abstract
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
9 Citations
58 Claims
- 1. A method of administering pirfenidone to treat a patient who would benefit from pirfenidone administration, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, comprising (a) administering to said patient pirfenidone at doses of at least 1600 mg/day or 1602 mg/day.
-
9. (canceled)
-
12-31. -31. (canceled)
-
36. (canceled)
-
39-54. -54. (canceled)
Specification